source
- Novartis IL-6 antibody pacibekitug cuts inflammation markers in Phase 2 studyA Phase 2 trial called TRANQUILITY showed that pacibekitug, an IL-6‑targeting antibody acquired by Novartis, reduced several biomarkers of inflammation in participants. The reductions were sustain…
- FDA approves Mimrylo, first hepcidin-mimicking drug for polycythemia veraThe U.S. Food and Drug Administration announced approval of Mimrylo (rusfertide) for adult patients with polycythemia vera, a rare blood disorder that causes excess red blood cells. The drug mimic…